¥22.68   ( %)
前日收盘: 当日成交量(股): 当日最高: 总股本:1717.97万
当日开盘: 当日成交额(元): 当日最低: 流通股本:
市盈率(动/静):0/0 市净率:0 市销率:0 总市值:3.90亿
52周最高:25.57 52周最低:7.73 转让方式: 单位:美元
$KalVista(KALV)$
  • 还可以输入
  • 20016

KalVista(KALV) 12月15日 09时26分

查看全文

KalVista(KALV) 12月15日 09时26分

查看全文

KalVista(KALV) 12月15日 08时09分

新闻 KalVista Pharmaceuticals Reports Fiscal Second Quarter Results
- KVD900 Enlarged Phase 2 Trial on Track for Potential On-DemandTreatment of Attacks in Patients with Hered ......  url.vc.watch/nV7t
查看全文

KalVista(KALV) 12月15日 02时12分

KalVista(KALV) 11月12日 23时56分

新闻 KalVista Pharmaceuticals Provides Clinical Update on KVD900
- Enlarged Phase 2 Study to Begin in 2018 for Potential AcuteTreatment of Hereditary Angioedema; Data Expected ......  url.vc.watch/n9PA
查看全文

KalVista(KALV) 11月07日 00时23分

新闻 KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: ......  url.vc.watch/n6ej
查看全文

KalVista(KALV) 10月08日 07时14分

公告 KalVista Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Unkart Edward W
公告日:2018-10-05, 内部交易人:Unkart Edward W, 与发行人关系:/董事/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-10-03, SEC Accession No. 0001567619-18-003784, File:https://www.sec.gov/Archives/edgar/data/1348911/000156761918003784/0001567619-18-003784-index.htm $KalVista(KALV)$
查看全文

KalVista(KALV) 10月08日 07时14分

公告 KalVista Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:ORONSKY ARNOLD L
公告日:2018-10-05, 内部交易人:ORONSKY ARNOLD L, 与发行人关系:/董事/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-10-03, SEC Accession No. 0001567619-18-003783, File:https://www.sec.gov/Archives/edgar/data/1348911/000156761918003783/0001567619-18-003783-index.htm $KalVista(KALV)$
查看全文

KalVista(KALV) 10月08日 07时14分

公告 KalVista Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Cha Albert
公告日:2018-10-05, 内部交易人:Cha Albert, 与发行人关系:/董事/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-10-03, SEC Accession No. 0001567619-18-003782, File:https://www.sec.gov/Archives/edgar/data/1348911/000156761918003782/0001567619-18-003782-index.htm $KalVista(KALV)$
查看全文

KalVista(KALV) 10月08日 07时14分

公告 KalVista Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:ALDRICH RICHARD
公告日:2018-10-05, 内部交易人:ALDRICH RICHARD, 与发行人关系:/董事/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-10-03, SEC Accession No. 0001567619-18-003781, File:https://www.sec.gov/Archives/edgar/data/1348911/000156761918003781/0001567619-18-003781-index.htm $KalVista(KALV)$
查看全文

KalVista(KALV) 10月08日 07时14分

KalVista(KALV) 09月28日 19时55分

KalVista(KALV) 09月28日 19时55分

KalVista(KALV) 09月26日 18时14分

新闻 KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (N ......  url.vc.watch/JNJC
查看全文

KalVista(KALV) 09月21日 16时22分

公告 KalVista Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Maetzel Andreas
公告日:2018-09-20, 内部交易人:Maetzel Andreas, 与发行人关系:Senior Vice President Medical/高管/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-09-18, SEC Accession No. 0001567619-18-002985, File:https://www.sec.gov/Archives/edgar/data/1348911/000156761918002985/0001567619-18-002985-index.htm $KalVista(KALV)$
查看全文

KalVista(KALV) 09月21日 16时22分

公告 KalVista Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Feener Edward P.
公告日:2018-09-20, 内部交易人:Feener Edward P., 与发行人关系:Chief Scientific Officer/高管/, 操作码:A,12500(股)Common Stock; 操作码:F,2500(股)Common Stock; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-09-18, SEC Accession No. 0001567619-18-002984, File:https://www.sec.gov/Archives/edgar/data/1348911/000156761918002984/0001567619-18-002984-index.htm $KalVista(KALV)$
查看全文

KalVista(KALV) 09月21日 16时22分

公告 KalVista Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Yea Christopher
公告日:2018-09-20, 内部交易人:Yea Christopher, 与发行人关系:Chief Development Officer/高管/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-09-18, SEC Accession No. 0001567619-18-002983, File:https://www.sec.gov/Archives/edgar/data/1348911/000156761918002983/0001567619-18-002983-index.htm $KalVista(KALV)$
查看全文

KalVista(KALV) 09月21日 16时22分

公告 KalVista Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Palleiko Benjamin L
公告日:2018-09-20, 内部交易人:Palleiko Benjamin L, 与发行人关系:CFO and Secretary/高管/, 操作码:A,32500(股)Common Stock; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-09-18, SEC Accession No. 0001567619-18-002982, File:https://www.sec.gov/Archives/edgar/data/1348911/000156761918002982/0001567619-18-002982-index.htm $KalVista(KALV)$
查看全文

KalVista(KALV) 09月21日 16时22分

公告 KalVista Pharmaceuticals, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Crockett Thomas Andrew
公告日:2018-09-20, 内部交易人:Crockett Thomas Andrew, 与发行人关系:CEO/董事/高管/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-09-18, SEC Accession No. 0001567619-18-002981, File:https://www.sec.gov/Archives/edgar/data/1348911/000156761918002981/0001567619-18-002981-index.htm $KalVista(KALV)$
查看全文

KalVista(KALV) 09月17日 01时14分

新闻 KalVista Pharmaceuticals Reports Fiscal First Quarter Results
- KVD900 Phase 2 On Track to Begin in 2018 for Potential On-DemandTreatment of Acute Attacks in Patients wit ......  url.vc.watch/Jlzq
查看全文
  • 首页 上一页 1 2 下一页 尾页  每页20条/共24